Reading this on a mobile device? Try our optimized mobile version here:

January 30, 2013News for medical technology professionals

  Top Story 
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Business & Market Trends 
  • LipoScience pulls in $45 million from public offering
    LipoScience has secured $45 million in a just-completed initial public offering. The Raleigh, N.C.-based in vitro diagnostics company plans to use about $38.6 million in expected net proceeds from the offering in part to fund its research and development projects, including initiatives to increase its Vantera system's test menu. Clinica (subscription required) (1/29) LinkedInFacebookTwitterEmail this Story
  International Developments 
Eucomed represents the medical technology industry in Europe. Our mission is to make modern, innovative and reliable medical technology available to more people. AdvaMed and Eucomed partner on issues of mutual interest.
  • ReCor wins EU approval for 2nd-gen renal denervation device
    ReCor Medical has been cleared to market a new version of its ultrasound-based renal denervation device, which is used to control hypertension, in Europe. The PARADISE Gen 2 system improves on the original version with faster denervation and a 6 French over-the-wire device size. (1/29) LinkedInFacebookTwitterEmail this Story
  Science & Health 
  • Portable device analyzes gait
    A new gait analysis tool that is strapped to the patient’s leg uses sensors to measure 3D acceleration, 3D rotational velocity and absolute direction of movement. When the device is near a Wi-Fi server, it analyzes the data, produces a report and transmits it to the clinician. “It’s ... a way for doctors to save money by outsourcing the analysis, instead of maintaining a lab to do so on-site,” said Tal Anker, CEO of SensoGo, the Israel company that developed the product. The Times of Israel (1/28) LinkedInFacebookTwitterEmail this Story
  • Former soldier receives double arm transplant
    The first service member from the Iraq and Afghanistan wars to survive the loss of four limbs has undergone a double-arm transplant at Johns Hopkins Hospital in Baltimore. Brendan Marrocco, who lost his left arm below the elbow and his right arm above the elbow, is also the first service member to receive a double arm transplant. Now, a month after the transplant, he is one of only seven people in the country to have undergone the procedure successfully. The Washington Post (1/28) LinkedInFacebookTwitterEmail this Story
  Emerging Technologies 
  • Sightpath aims for U.S. rollout of cataract laser this year
    Sightpath Medical said it aims to debut its mobile femtosecond laser for use in cataract surgery early this year. The MoFeTM service suite, which is targeted for a national rollout throughout the year, features an intra-operative wavefront aberrometer, a femtosecond laser and a certified laser engineer. (1/29) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising with SmartBrief? Click here for detailed industry information and media kits. 

  Government & Regulatory 
  • AdvaMed, others remobilize efforts to repeal 2.3% device tax
    AdvaMed and two other industry groups continue to press Congress to repeal the 2.3% medical device tax as the first payment due date has arrived. "This tax is already resulting in layoffs, reduced investments in R&D and delays in significant capital improvements. We urge Congress to act swiftly and repeal this job-killing, innovation destroying, anti-competitive tax," AdvaMed President and CEO Stephen Ubl said. (Boston) (1/29) LinkedInFacebookTwitterEmail this Story
  • For more: Read the AdvaMed press release about the industry's first device tax payment and the group's continued efforts to repeal the tax.
AdvaMed News 
  • Join the AdvaMed-MTLI LinkedIn group!
    Build close relationships with member companies, both small and large, and receive an intimate understanding of the key issues affecting innovation, access and the bottom line. Interact in discussions that leverage the leadership and expertise of the medical technology industry. This social group is full of key stakeholders, influencers and industry thought leaders as well as regulatory and policy experts from the FDA and CMS. Aside from practical learning opportunities, this LinkedIn group provides the premier opportunity to network with key players from virtually every aspect of the industry. Link to the AdvaMed MTLI LinkedIn group page. LinkedInFacebookTwitterEmail this Story
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

Position TitleCompany NameLocation
Neurovascular Intervention Marketing ManagerAsahi InteccSanta Ana, CA
Sr. QA Manager - Quality Systems (Santa Barbara)AllerganSanta Barbara, CA
Regional Service Manager PhilipsHartford, CT
Quality Systems ManagerRoche DiagnosticsIndianapolis, IN
Product Support Specialist IVArthroCare CorporationAustin, TX
Director of Clinical AffairsEndologixIrvine, CA
Sr. Clinical Research AssociateEndologix, Inc.Irvine, CA
Area Reimbursement Manager (Central U.S. or Northeast U.S.)SI-BONE, IncMultiple Locations, United States
Program Director, Regulatory AffairsJohnson & JohnsonFremont, CA
Click here to view more job listings.

Resentment is like taking poison and waiting for the other person to die."
--Malachy McCourt,
Irish-American actor, writer and politician

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
A powerful website for SmartBrief readers including:
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information